Treatment of CML cells with bortezomib results in downregulation of S-phase kinase protein 2 (SKP2) and concomitant stabilization of the expression of p27Kip1. This evidence concerns the gene SKP2 and chronic myelogenous leukemia, BCR-ABL1 positive.